Development of Biomarker Signatures Associated with Anoikis to Predict Prognosis in Endometrial Carcinoma Patients

Figure 8

Analysis of immunotherapy response of EC patients. (a) TIDE score in two groups. (b) CAF score in two groups. (c) MDSC score in two groups. (d) T-cell exclusion score in two groups. (e) T-cell dysfunction score in two groups.

(a)

(b)

(c)

(d)

(e)